Cetuximab MMAE
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity[1].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR; Microtubule/Tubulin
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.53
Smiles
[CetuximabMMAE]
Molecular Weight
150804 (average)
References & Citations
[1]Kyoji Tsuchikama, et al. Exploring the next generation of antibody–drug conjugates. Review Nat Rev Clin Oncol. 2024 Mar;21 (3) :203-223.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940745-500 1x 500 µL
CD45 / LCA (2B11 + PD7/26), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880008-100 1x 100 µL
MAGE A1 (MA454), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741073-500 1x 500 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details